MIND MEDICINE MINDMED INC. [MMEDF: OTCQB]

1.6557 -0.0543 (-3.18%) 11/30/2020 Delayed 15 minutes

Open	$1.89	Daily Range	$1.64-$1.89
Prev. Close	$1.71	52 Week Range	$0.0833-$1.98
Volume	4,640,116

Quote Data Realtime

Inside Quote
Bid	Ask	Last Inside Change
$1.66 x 3540 shares	$1.67 x 5700 shares	11/30 5:00 PM EST

Level II Quote Montage

BID

ASK

MMID	Bid Price	Bid Size	Date/Time
CDEL	1.66	2800	15:59
CSTI	1.66	600	15:59
NITE	1.66	140	15:59
INTL	1.65	1550	15:56
GTSM	1.65	1000	15:51
JANE	1.64	5000	15:59
ETRF	1.63	100	15:56
OTCX	1.61	2700	15:59
LAFC	0.6572	1000	10/28
MAXM	0.6572	1000	07:35
MCAP	0.20	2500	15:55
PUMA	0.0001	10000	08:10
BGCE	U		11/25
VALX	U		15:59

MMID	Ask Price	Ask Size	Date/Time
JANE	1.67	5000	15:59
INTL	1.67	600	15:58
ETRF	1.67	100	15:59
CSTI	1.68	5000	15:56
CDEL	1.69	25050	15:59
NITE	1.70	4616	15:49
GTSM	1.77	100	14:42
OTCX	1.83	30800	15:59
MAXM	2.29	100	07:35
PUMA	2.58	100	08:10
MCAP	2.82	100	15:55
LAFC	3.02	100	11/20
BGCE	U		11/25
VALX	U		15:59

The quotes displayed here are published by market makers on the OTC Markets Group Inc. electronic inter-dealer quotation and trading system for OTC securities. Please see Terms of Service and Risk Warning for more information.

MMID - Market maker quotation published in OTC Link that meets the Inside market | MMID - Market maker quotation published in OTC Link | cMMID - Closed quote | Unpriced - Unpriced quote in OTC Link | MMIDu - Unsolicited market maker quotation published in OTC Link

Breakthrough Mental Healing

We help patients unlock the healing power of the mind through Psychedelic Inspired Medicines & Experiential Therapies.

Together we can overcome.

11/25/20

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

We're Creating a New Toolset for Mental Health & Addiction

Solving for mental illness and addiction requires a novel approach

ANXIETY

Experiential Therapies

Transcending traditional mental healthcare to treat Anxiety

ADHD & ADDICTION

Psychedelic Inspired Medicines

Unlocking a new kind of healing for ADHD & Addiction

Psychedelic Innovation

Next-Gen R&D

Developing new compounds, therapies, methods and technologies to optimize patient outcomes

Advancing Psychedelic Inspired Medicines & Experiential Therapies Through Clinical Trials

We’re a New Kind of Pharma Company

Patients and therapists deserve care that transcends traditional symptom management cycles, advancing long-term mental healing.

View our approach

Our Healing Goes Beyond Just A Pill

01

Discover

Rigorous science of novel psychedelic compounds, therapies, and healing technologies in collaboration with leading institutions and researchers to make faster discoveries, together

02

Develop

Conducting clinical trials of psychedelic inspired medicines and experiential therapies within existing regulatory pathways to ensure the most effective & transformative healing experience possible

03

Deploy

We hold ourselves and our products to the highest levels of safety, efficacy, and accessibility so psychedelic inspired medicines and experiential therapies can one day reach patients in need

Partnerships

Groundbreaking R&D In the Birthplace of LSD: Basel, Switzerland

Partnerships

Training a New Generation of Psychiatrists at NYU

Partnerships

Studying the Science of Microdosing with Experts at Maastricht University

Press Release

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

Press Release

MindMed Upsizes Previously Announced Bought Deal Public Offering

Press Release

MindMed Announces $25 Million Bought Deal Public Offering

Press Release

MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities

Press Release

MindMed Announces Q3 2020 Financial Results; Cash Reserves Total $37.8 million USD ($50.1 million CAD) Post October Financing

More News

IN THE PRESS

This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?”

Shark Tank's Kevin O' Leary MindMed Investor

MindMed named one of 36 startups that could change the world

MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”

Meet the Team

Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.

MEET MINDMED